Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: A retrospective clinical study

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2198-2208

  Pollard, Rodney P E ^a   Pijpe, Justin ^a   Bootsma, Hendrika ^a   Spijkervet, Fred K L ^a   Kluin, Philip M ^a   Roodenburg, Jan L N ^a   Kallenberg, Cees G M ^a   Vissink, Arjan ^a   Van Imhoff, Gustaaf W ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Mucosa associated lymphoid tissue lymphoma; Sj gren's syndrome

Indexed keywords

CRYOGLOBULIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M; M PROTEIN; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; OUTCOME ASSESSMENT; PAROTID GLAND CANCER; PAROTIDECTOMY; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SJOEGREN SYNDROME; TREATMENT RESPONSE; WATCHFUL WAITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PAROTID GLAND; PAROTID NEOPLASMS; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 80053488218     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110077     Document Type: Article

References (59)

1. Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 1998;28:80-7. (Pubitemid 28480892)
2. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803. (Pubitemid 43799181)
3. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92. (Pubitemid 9087322)
4. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996;39:767-72.
5. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's syndrome. Arthritis Rheum 1999;42:1765-72. (Pubitemid 30263648)
6. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38.
7. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
8. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7. (Pubitemid 34214255)
9. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology 2005;44:89-94. (Pubitemid 40124338)
10. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9. (Pubitemid 38480838)
11. Kraaijenhagen HA. Technique for parotid biopsy [letter]. J Oral Surg 1975;33:328.
12. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one-third of 158 patients analyzed. Blood 2000;95:802-6. (Pubitemid 30062699)
13. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-95. (Pubitemid 36857603)
14. Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997;15:1624-30. (Pubitemid 27167402)
15. Coupland SE, Krause L, Delecluse HJ, Anagnostopoulos I, Foss HD, Hummel M, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 1998;105:1430-41. (Pubitemid 28509761)
16. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-75. (Pubitemid 27299117)
17. Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004;126:43-9. (Pubitemid 38859480)
18. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104. (Pubitemid 34162980)
19. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-94. (Pubitemid 38584982)
20. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-48. (Pubitemid 38067636)
21. Roggero E, Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263-8. (Pubitemid 30090662)
22. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005;307-13.
23. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-64. (Pubitemid 46606184)
24. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212. (Pubitemid 44560804)
25. Haas RL, Poortmans P, De Jong D, Aleman BM, Dewit LG, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003;21:2474-80. (Pubitemid 46606327)
26. Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, et al. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol 2008; 19:2043-7.
27. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab mono-therapy in a patient with Sjogren's syndrome and associated MALT-lymphoma. Ann Rheum Dis 2005;64:958-60. (Pubitemid 40733928)
28. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-9.
29. Thieblemont C, De la Fouchardiere A, Coiffier B. Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma 2003;3:212-24. (Pubitemid 36416845)
30. Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999;17:1254.
31. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42. (Pubitemid 34438862)
32. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non- Hodgkin's lymphoma. Blood 1997;90:2188-95. (Pubitemid 27392702)
33. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. (Pubitemid 40223656)
34. Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel, B et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009;20:326-30.
35. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-5. (Pubitemid 37248842)
36. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-83. (Pubitemid 46211377)
37. Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 2004;73:258-62. (Pubitemid 39294690)
38. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum 2005;52:2740-50. (Pubitemid 41369102)
39. Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-10. (Pubitemid 38064941)
40. Meijer J, Meiners P, Vissink A, Spijkervet F, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
41. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
42. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
43. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology 2007;46:335-41. (Pubitemid 46189797)
44. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317. (Pubitemid 38072572)
45. Sandberg Y, Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn 2005;7:495-503. (Pubitemid 41479716)
46. Quintana PG, Kapadia SB, Bahler DW, Johnson JT, Swerdlow SH. Salivary gland lymphoid infiltrates associated with lymphoepithelial lesions: a clinicopathologic, immunophenotypic, and genotypic study. Hum Pathol 1997;28:850-61. (Pubitemid 27298973)
47. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6. (Pubitemid 19272832)
48. Musshoff K. [Clinical staging classification of non-Hodgkin's lymphomas (author's transl)]. Strahlentherapie 1977;153:218-21.
49. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53. (Pubitemid 29162950)
50. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
51. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9. Erratum in: Ann Rheum Dis 2011;70:880.
52. Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, et al. Sjögren's Systemic Clinical Activity Index (SCAI) - a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology 2007;46:1845-51. (Pubitemid 350168303)
53. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 2007;66:107-12. (Pubitemid 46044868)
54. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005;32:143-9.
55. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology Am Soc Hematol Educ Program 2001;241-58.
56. Batsakis JG. Primary lymphomas of the major salivary glands. Ann Otol Rhinol Laryngol 1986;95:107-8.
57. Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006; 11:285-91.
58. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005;14:210-4. (Pubitemid 40445585)
59. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76. (Pubitemid 29022402)